Trial Profile
A Phase II Study of Pemetrexed and Gefitinib in Chemotherapy Naive Patients with Non-Small Cell Lung Cancer Harboring Mutations of EGFR
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jun 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 11 Aug 2011 New trial record